A weakly supervised deep learning approach for label-free imaging flow-cytometry-based blood diagnostics.

Journal: Cell reports methods
PMID:

Abstract

The application of machine learning approaches to imaging flow cytometry (IFC) data has the potential to transform the diagnosis of hematological diseases. However, the need for manually labeled single-cell images for machine learning model training has severely limited its clinical application. To address this, we present iCellCnn, a weakly supervised deep learning approach for label-free IFC-based blood diagnostics. We demonstrate the capability of iCellCnn to achieve diagnosis of Sézary syndrome (SS) from patient samples on the basis of bright-field IFC images of T cells obtained after fluorescence-activated cell sorting of human peripheral blood mononuclear cell specimens. With a sample size of four healthy donors and five SS patients, iCellCnn achieved a 100% classification accuracy. As iCellCnn is not restricted to the diagnosis of SS, we expect such weakly supervised approaches to tap the diagnostic potential of IFC by providing automatic data-driven diagnosis of diseases with so-far unknown morphological manifestations.

Authors

  • Corin F Otesteanu
    Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • Martina Ugrinic
    Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland.
  • Gregor Holzner
    Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland.
  • Yun-Tsan Chang
    Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Christina Fassnacht
    Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Emmanuella Guenova
    Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Stavros Stavrakis
    Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland.
  • Andrew deMello
    Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland.
  • Manfred Claassen
    Internal Medicine I, University Hospital Tübingen, Faculty of Medicine, University of Tübingen, Tübingen, Germany.